Journal Article > ResearchFull Text
Bull World Health Organ. 2015 June 25; Volume 93 (Issue 9); 623-630.; DOI:10.2471/BLT.14.146480
Fajardo E, Metcalf CJ, Piriou E, Gueguen M, Maman D, et al.
Bull World Health Organ. 2015 June 25; Volume 93 (Issue 9); 623-630.; DOI:10.2471/BLT.14.146480
OBJECTIVE
To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associated with invalid results.
METHODS
We collated 25,616 CD4+ T-lymphocyte test results from 39 sites in nine countries for the years 2011 to 2013. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully; if not, an invalid result is reported. We calculated the proportion of invalid results by device and by operator. Regression analyses were used to investigate factors associated with invalid results.
FINDINGS
There were 3354 invalid test results (13.1%) across 39 sites, for 58 Alere PimaTM devices and 180 operators. The median proportion of errors per device and operator was 12.7% (interquartile range, IQR: 10.3-19.9) and 12.1% (IQR: 7.1-19.2), respectively. The proportion of invalid results varied widely by country, setting, user and device. Errors were not associated with settings, user experience or the number of users per device. Tests performed on capillary blood samples were significantly less likely to generate errors compared to venous whole blood.
CONCLUSION
The Alere Pima CD4+ analyser generated a high proportion of invalid test results, across different countries, settings and users. Most error codes could be attributed to the operator, but the exact causes proved difficult to identify. Invalid results need to be factored into the implementation and operational costs of routine CD4+ T-lymphocyte testing.
To estimate the proportion of invalid results generated by a CD4+ T-lymphocyte analyser used by Médecins Sans Frontières (MSF) in field projects and identify factors associated with invalid results.
METHODS
We collated 25,616 CD4+ T-lymphocyte test results from 39 sites in nine countries for the years 2011 to 2013. Information about the setting, user, training, sampling technique and device repair history were obtained by questionnaire. The analyser performs a series of checks to ensure that all steps of the analysis are completed successfully; if not, an invalid result is reported. We calculated the proportion of invalid results by device and by operator. Regression analyses were used to investigate factors associated with invalid results.
FINDINGS
There were 3354 invalid test results (13.1%) across 39 sites, for 58 Alere PimaTM devices and 180 operators. The median proportion of errors per device and operator was 12.7% (interquartile range, IQR: 10.3-19.9) and 12.1% (IQR: 7.1-19.2), respectively. The proportion of invalid results varied widely by country, setting, user and device. Errors were not associated with settings, user experience or the number of users per device. Tests performed on capillary blood samples were significantly less likely to generate errors compared to venous whole blood.
CONCLUSION
The Alere Pima CD4+ analyser generated a high proportion of invalid test results, across different countries, settings and users. Most error codes could be attributed to the operator, but the exact causes proved difficult to identify. Invalid results need to be factored into the implementation and operational costs of routine CD4+ T-lymphocyte testing.
Journal Article > ResearchFull Text
HIV/AIDS Res Treat Open J. 2015 May 11; Volume 2 (Issue 2); 44-50.; DOI:10.17140/HARTOJ-2-107
Vandendyck M, Motsamai M, Mubanga M, Makhakhe S, Tunggal S, et al.
HIV/AIDS Res Treat Open J. 2015 May 11; Volume 2 (Issue 2); 44-50.; DOI:10.17140/HARTOJ-2-107
OBJECTIVES
We conducted a mixed method study to evaluate the pilot of community ART groups (CAG’s) in Lesotho.
METHODS
At the end of 2012 CAGs were piloted in Nazareth clinic, a facility in rural Lesotho. In CAG’s stable patients take turns to collect antiretroviral therapy (ART) for fellow group members. Kaplan-Meier techniques were used to estimate retention among stable patients in CAG and not in CAG. Eight focus group discussions with 40 purposively selected CAG members, nine village health workers, six community leaders and nine clinicians provided insights in how CAGs are perceived by different stakeholders. The thematic analysis approach was employed for data analysis.
RESULTS
Among 596 stable patients 199 (33%) had joined a CAG. One year retention among CAG members and patients not in CAG was 98.7% (95% CI, 94.9-99.7) and 90.2% (95% CI, 86.6-92.9) respectively. CAG members commented that membership in CAG: 1) reduced time, effort, and money spent to get a monthly ART refill; 2) induced peer support, which enhanced adherence, socio-economic support and empowered members to deal with stigma; and 3) resulted in a feeling of relief and comfort. Village health workers confirmed increased openness about HIV in their community. Community leaders added that CAG members promoted health seeking behaviour to community members. Clinicians reported a workload reduction.
CONCLUSION
Participation in CAG impacted positively on the lives of members, not only on their access to ART, but also on their life within the community.
We conducted a mixed method study to evaluate the pilot of community ART groups (CAG’s) in Lesotho.
METHODS
At the end of 2012 CAGs were piloted in Nazareth clinic, a facility in rural Lesotho. In CAG’s stable patients take turns to collect antiretroviral therapy (ART) for fellow group members. Kaplan-Meier techniques were used to estimate retention among stable patients in CAG and not in CAG. Eight focus group discussions with 40 purposively selected CAG members, nine village health workers, six community leaders and nine clinicians provided insights in how CAGs are perceived by different stakeholders. The thematic analysis approach was employed for data analysis.
RESULTS
Among 596 stable patients 199 (33%) had joined a CAG. One year retention among CAG members and patients not in CAG was 98.7% (95% CI, 94.9-99.7) and 90.2% (95% CI, 86.6-92.9) respectively. CAG members commented that membership in CAG: 1) reduced time, effort, and money spent to get a monthly ART refill; 2) induced peer support, which enhanced adherence, socio-economic support and empowered members to deal with stigma; and 3) resulted in a feeling of relief and comfort. Village health workers confirmed increased openness about HIV in their community. Community leaders added that CAG members promoted health seeking behaviour to community members. Clinicians reported a workload reduction.
CONCLUSION
Participation in CAG impacted positively on the lives of members, not only on their access to ART, but also on their life within the community.